158 related articles for article (PubMed ID: 16275676)
1. A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Tsuburaya A; Sakamoto J; Morita S; Kodera Y; Kobayashi M; Miyashita Y; Macdonald JS
Jpn J Clin Oncol; 2005 Nov; 35(11):672-5. PubMed ID: 16275676
[TBL] [Abstract][Full Text] [Related]
2. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
3. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Morita S; Baba H; Tsuburaya A; Takiuchi H; Matsui T; Maehara Y; Sakamoto J
Jpn J Clin Oncol; 2007 Jun; 37(6):469-72. PubMed ID: 17584825
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
6. [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
Tamura S; Miki H; Okada K; Yoshimura M; Uji K; Yoshida A; Suzuki R; Nakahira S; Egawa C; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2024-6. PubMed ID: 19106511
[TBL] [Abstract][Full Text] [Related]
7. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa T; Tsuburaya A; Morita S; Kodera Y; Ito S; Cho H; Miyashita Y; Sakamoto J
Jpn J Clin Oncol; 2010 Apr; 40(4):369-72. PubMed ID: 20299499
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
9. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer.
Narahara H; Fujitani K; Takiuchi H; Sugimoto N; Inoue K; Uedo N; Tsukuma H; Tsujinaka T; Furukawa H; Taguchi T
Oncology; 2008; 74(1-2):37-41. PubMed ID: 18544958
[TBL] [Abstract][Full Text] [Related]
12. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy of gastric cancer with oral UFT (a mixture of uracil and fturafur) during the waiting period for surgery.
Nio Y; Sato Y; Nagami H; Teramoto M; Inoue Y; Yano S; Sumi S; Tamura K; Fukumoto M
Anticancer Res; 1998; 18(1B):523-30. PubMed ID: 9568172
[TBL] [Abstract][Full Text] [Related]
14. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
Hasegawa K; Takayama T; Ijichi M; Matsuyama Y; Imamura H; Sano K; Sugawara Y; Kokudo N; Makuuchi M
Hepatology; 2006 Oct; 44(4):891-5. PubMed ID: 17006925
[TBL] [Abstract][Full Text] [Related]
15. [Interim report of JFMC study no. 23--phase III randomized clinical trial on the effectiveness of low-dose cisplatin plus 5-FU as a postoperative adjuvant chemotherapy for advanced gastric cancer].
Saji S; Toge T; Kurosu Y; Hirata K; Gochi A; Tominaga S; Inokuchi K
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2499-507. PubMed ID: 12506472
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
[TBL] [Abstract][Full Text] [Related]
17. [Study on the intensity of MMC and UFT in postoperative adjuvant chemotherapy for gastric cancer--study report of JFMTC Study No. 10].
Danno M; Shiroto H; Kunii Y; Ishibiki K; Yamamura Y; Sakamoto Y; Tamura Y; Kunitomo K; Kumashiro R;
Gan To Kagaku Ryoho; 2001 Feb; 28(2):195-203. PubMed ID: 11242646
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Ohashi M; Kanda T; Yajima K; Banba T; Tanabe T; Kosugi S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1640-2. PubMed ID: 16315894
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy with UFT or UFT with OK-432 to patients with gastric and colorectal cancer. Kanto Adjuvant Study Group].
Konishi T; Idezuki Y; Watanabe H; Haga S; Ushirokouji Y; Shinohara K; Shibusawa M; Bandai Y; Hiraishi M; Murata N; Yabe K; Yamamura T; Yumoto S; Gunji A; Nishigaki M
Gan To Kagaku Ryoho; 1998 May; 25(6):887-900. PubMed ID: 9617328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
